Kiora Pharmaceuticals (KPRX) Times Interest Earned (2017 - 2026)
Kiora Pharmaceuticals' (KPRX) quarterly Times Interest Earned came in at -$103.92 in Q1 2026, up 43.33% YoY from -$72.51 in Q1 2025, and up 100.0% on a QoQ basis from -$7.3 million in Q4 2025.
Kiora Pharmaceuticals (KPRX) Times Interest Earned (2017 - 2026) Analysis & Trends
Kiora Pharmaceuticals (KPRX) has 10 years of Times Interest Earned data on file, last reported at -$103.92 in Q1 2026.
- Quarterly Times Interest Earned rose 43.33% year-over-year to -$103.92 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$538.67 (up 38.01% YoY) and the FY2025 annual result came in at -$0.76, down 321.67% from the prior year.
- Times Interest Earned climbed to -$103.92 in Q1 2026, from -$7.3 million in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of $1065.3 in Q1 2024 to a low of -$7.3 million in Q4 2025.
- A 5-year average of -$430159.6 and a median of -$61.1 in 2025 frame the typical range for Times Interest Earned.
- Annual changes were most pronounced in 2024 — Times Interest Earned soared 143.63% — and 2025, when it slumped 3745132853.15%.
- Tracing KPRX's Times Interest Earned over 5 years: stood at $22.98 in 2022, then plunged by 100.28% to -$0.06 in 2023, then plunged by 204.26% to -$0.2 in 2024, then tumbled by 3745132853.15% to -$7.3 million in 2025, then soared by 100.0% to -$103.92 in 2026.
- The last three Times Interest Earned figures came in at -$103.92 (Q1 2026), -$7.3 million (Q4 2025), and -$24.07 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Kiora Pharmaceuticals | 15.64 Mn | 15.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.29 |
| Mar 31, 2026 | -103.92 |
| Dec 31, 2025 | -7.31 Mn |
| Sep 30, 2025 | -24.07 |
| Jun 30, 2025 | -61.10 |
| Mar 31, 2025 | -183.39 |
| Dec 31, 2024 | -0.20 |
| Sep 30, 2024 | -386.59 |
| Jun 30, 2024 | -27.41 |
| Mar 31, 2024 | 1,065.27 |
| Dec 31, 2023 | -0.06 |
| Sep 30, 2023 | -316.08 |
| Jun 30, 2023 | -67.19 |
| Mar 31, 2023 | -2,441.61 |
| Dec 31, 2022 | 22.98 |
| Sep 30, 2022 | -26.50 |
| Jun 30, 2022 | -13.61 |
| Mar 31, 2022 | -63.99 |
| Dec 31, 2021 | 63.19 |
| Sep 30, 2021 | -120.62 |